CN111670049A - 用于预防或治疗免疫疾病的ripk1和ikk抑制剂的组合 - Google Patents

用于预防或治疗免疫疾病的ripk1和ikk抑制剂的组合 Download PDF

Info

Publication number
CN111670049A
CN111670049A CN201880088634.3A CN201880088634A CN111670049A CN 111670049 A CN111670049 A CN 111670049A CN 201880088634 A CN201880088634 A CN 201880088634A CN 111670049 A CN111670049 A CN 111670049A
Authority
CN
China
Prior art keywords
inhibitor
ripk1
ikk
leu
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880088634.3A
Other languages
English (en)
Chinese (zh)
Inventor
马诺利斯·帕斯帕拉基斯
尼科斯·奥科诺穆
阿波斯托洛斯·波尔多拉蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet zu Koeln
Original Assignee
Universitaet zu Koeln
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet zu Koeln filed Critical Universitaet zu Koeln
Publication of CN111670049A publication Critical patent/CN111670049A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880088634.3A 2017-12-07 2018-12-07 用于预防或治疗免疫疾病的ripk1和ikk抑制剂的组合 Pending CN111670049A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17205864.6A EP3494994A1 (en) 2017-12-07 2017-12-07 Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases
EP17205864.6 2017-12-07
PCT/EP2018/084055 WO2019110832A1 (en) 2017-12-07 2018-12-07 Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases

Publications (1)

Publication Number Publication Date
CN111670049A true CN111670049A (zh) 2020-09-15

Family

ID=60629504

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880088634.3A Pending CN111670049A (zh) 2017-12-07 2018-12-07 用于预防或治疗免疫疾病的ripk1和ikk抑制剂的组合

Country Status (7)

Country Link
US (1) US20200383995A1 (https=)
EP (2) EP3494994A1 (https=)
JP (1) JP7527639B2 (https=)
CN (1) CN111670049A (https=)
CA (1) CA3103847A1 (https=)
MX (1) MX2020007036A (https=)
WO (1) WO2019110832A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119064582A (zh) * 2024-09-02 2024-12-03 南方医科大学南方医院 RIPK1 O-GlcNAc糖基化抑制剂在制备增强肾细胞癌舒尼替尼敏感性药物中的应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021046515A1 (en) * 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
IL291665B2 (en) 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
JP2023502514A (ja) 2019-11-26 2023-01-24 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム 疾患の処置のための受容体相互作用プロテインキナーゼｉの阻害剤
EP4209213A1 (en) * 2022-01-05 2023-07-12 Universität zu Köln Signalling-pathway inhibitor combinations for use in the treatment of cancer diseases
WO2024170776A1 (en) 2023-02-17 2024-08-22 Universität Zu Köln Triple kinase inhibition for the treatment of type i interferon response associated disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459980A (zh) * 2014-06-24 2017-02-22 奥图视生物技术公司 Tlr‑4特异性适配体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03006817A (es) * 2001-02-01 2003-11-13 Bristol Myers Squibb Co Metodo de tratamiento de enfermedades inflamatorias e inmunes usando inhibidores de la ikb cinasa (ikk).
JP2009539865A (ja) * 2006-06-06 2009-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換３−アミノ−チエノ［２，３−ｂ］ピリジン２−カルボン酸アミド化合物及び製造方法及びそれらの使用
EP3017825A1 (en) * 2014-11-06 2016-05-11 Ludwig-Maximilians-Universität München An inhibitor of the RIPK1-dependent necrosis pathway and a pharmaceutical composition comprising the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459980A (zh) * 2014-06-24 2017-02-22 奥图视生物技术公司 Tlr‑4特异性适配体及其应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FLORIAN R. GRETEN ET AL.: "NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKβ", 《CELL》 *
JOANN STRNAD AND JAMES R. BURKE: "IκB kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challenges", 《TRENDS IN PHARMACOLOGICAL SCIENCES》 *
YVES DONDELINGER ET AL.: "NF-κB-Independent Role of IKKα/IKKβ in Preventing RIPK1 Kinase-Dependent Apoptotic and Necroptotic Cell Death during TNF Signaling", 《MOLECULAR CELL》 *
ZHEN-YU LIU ET AL.: "Necrostatin-1 reduces intestinal inflammation and colitis-associated tumorigenesis in mice", 《AM J CANCER RES》 *
廖清奎主编: "《小儿血液学》", 30 April 2005, 天津科学技术出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119064582A (zh) * 2024-09-02 2024-12-03 南方医科大学南方医院 RIPK1 O-GlcNAc糖基化抑制剂在制备增强肾细胞癌舒尼替尼敏感性药物中的应用

Also Published As

Publication number Publication date
EP3720493C0 (en) 2024-07-24
EP3720493B1 (en) 2024-07-24
WO2019110832A1 (en) 2019-06-13
EP3720493A1 (en) 2020-10-14
JP7527639B2 (ja) 2024-08-05
CA3103847A1 (en) 2019-06-13
MX2020007036A (es) 2020-12-03
JP2021505611A (ja) 2021-02-18
US20200383995A1 (en) 2020-12-10
EP3494994A1 (en) 2019-06-12

Similar Documents

Publication Publication Date Title
JP7527639B2 (ja) 免疫疾患の予防または治療のためのｒｉｐｋ１阻害剤とｉｋｋ阻害剤の組み合わせ
B. Moore et al. Animal models of fibrotic lung disease
US20200277349A1 (en) N-terminally truncated interleukin-38
US20030171253A1 (en) Methods and compositions relating to modulation of A20
US9125862B2 (en) Methods for the treatment of Prader-Willi-like syndrome or non-organic failure to thrive (NOFITT) feeding disorder using an agonist of the oxytocin receptor
US7892539B2 (en) Modulation of an innate immune response by altering TRIAL-R signaling
CN102552910B (zh) 细胞外基质蛋白1及其调节剂在制备过敏性疾病诊断或治疗药物中的应用
US8771700B2 (en) Interferon antagonists, antibodies thereto and associated methods of use
US20070098722A1 (en) Medicament comprising inhibitors of long pentraxin ptx3
JP7374502B2 (ja) Ｏｃａ－ｂペプチドコンジュゲート及び処置方法
JP2020511418A (ja) Ｉｌｃ２細胞に関連する疾患を処置する方法
KR20090038336A (ko) 인터루킨-27, 인터루킨-27-에프씨 융합단백질 및 그돌연변이들을 포함하는 자가면역 질환의 예방 및 치료용약학적 조성물
WO2026056985A1 (zh) 抑郁症的治疗方法和药物组合物
Moore et al. Translational Review
KR20150123175A (ko) Dab2 유전자가 과발현된 수지상 세포를 포함하는 자가면역질환 예방 또는 치료용 약제학적 조성물
HK40100341A (zh) 靶向pacs1的化合物及其使用方法
HK40100718A (zh) 靶向wdr37的化合物及其使用方法
Vollrath et al. Role of Mertk in RPE phagocytosis and retinal disease
清水謙次 The role of Interleukin-1 receptor type 2 in the development of collagen-induced arthritis and helper T cell differentiation
WO2015163702A1 (ko) Dab2 유전자가 과발현된 수지상 세포를 포함하는 자가면역질환 예방 또는 치료용 약제학적 조성물
NZ786536A (en) Methods of treating diseases associated with ILC2 cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination